App-Quantinova.ai

Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets.

Lorie Ellis - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Trends in prescribing preferences (PPrefs) of U.S.-based oncologists for patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) following docetaxel (DO).

Charles J. Ryan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Feasibility analysis of pathology and genetic yield from a prospective trial of tissue biopsies in metastatic castrate-resistant prostate cancer (mCRPC).

Rafael E. Jimenez - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).

Benjamin Louis Maughan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting.

A. Oliver Sartor - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Dynamic changes of alkaline phosphatase as surrogate for best clinical benefit and overall survival during very early abiraterone therapy compared to PSA-changes in bone metastatic castration resistant prostate cancer.

Martin Boegemann - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use program in France.

Nadine Houede - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.

Joaquin Mateo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Drug-drug interactions in patients with castration-resistant prostate cancer undergoing abiraterone therapy: Characterizing the scale of the problem.

Rehana Jamani - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.

Akash Patnaik - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

CB-7598

IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone.

Sebastien J. Hotte - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Incidence of abiraterone acetate withdrawal response measured by PSA declines.

Rajasree Pia Chowdry - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

CB-7598

Testing a prognostic model in patients with metastatic castrate resistant prostate cancer (MCRPC) treated prechemotherapy with abiraterone.

Shermaine Pan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Pragmatic predictors of response to abiraterone in metastatic castrate resistant-prostate cancer.

Rhian Sian Davies - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

The predictive value of ARv7 expression in localized prostate caner treated with abiraterone, degarelix, and bicalutamide.

Niall Corcoran - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

CB-7598

Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dana E. Rathkopf - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone.

Jianqing Lin - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Phase 1 study of the PSMA-tubulysin small-molecule drug conjugate EC1169 in pts with metastatic castrate-resistant prostate cancer (mCRPC).

Samuel Ejadi - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).

Manish Kohli - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.

Robert B. Montgomery - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Filters

959 Abstracts